



Market Announcement

17 March 2025

Opthea Limited (ASX: OPT) – Trading Halt

Description

The securities of Opthea Limited ('OPT') will be placed in trading halt at the request of OPT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 19 March 2025 or when the announcement is released to the market.

Issued by

ASX Compliance



17 March 2025

Ms Melissa Kostopoulos
Senior Adviser, Listings Compliance (Melbourne)
ASX Compliance Pty Ltd
525 Collins Street
South Tower Level 50
Melbourne VIC 3000

By email: melissa.kostopoulos@asx.com.au / tradinghaltsmelbourne@asx.com.au

Dear Melissa

**Opthea Limited (ASX: OPT)
Request for Trading Halt**

Pursuant to Listing Rule 17.1, Opthea Limited (ACN 006 340 567) (**Opthea**) requests an immediate trading halt in its quoted securities (ASX Codes: OPT, OPTOA, OPTOB) to apply from the open of trading today, Monday, 17 March 2025.

The trading halt is requested pending a material announcement by Opthea to the market in relation to the top line results of its Phase 3 COAST (Combination OPT-302 with Aflibercept Study) clinical trial (the **COAST Results**).

In accordance with Listing Rule 17.1, Opthea provides the following information:

- the trading halt is requested pending the release of an announcement by Opthea in relation to the COAST Results;
- Opthea requests that the trading halt remain in place until an announcement to the market by Opthea in relation to the COAST Results or the commencement of trading on Wednesday, 19 March 2025; and
- Opthea is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market regarding the trading halt.

Yours sincerely

A handwritten signature in black ink, appearing to read "Karen Adams".

Karen Adams
Vice President Finance and Company Secretary